23-Mar-2020 | Facts and Factors
Findings from Facts and Factors report “Central Nervous System Disorder Therapeutics Market By Disease Type (Infectious Diseases, Neurodegenerative Diseases, Autoimmune & Inflammatory Diseases, Genetic Disorders, Cancers, Trauma and Psychiatric Disorders), By Drug Type (Analgesics, Nervous System Drugs, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others) and By Distribution Channel (Hospitals, Clinics, Homecare and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026” states that the global central nervous system disorder therapeutics market in 2019 is approximately USD 81.9 Billion. The market is expected to grow at a CAGR of 3.5 % and is anticipated to reach around USD 104.2 Billion by 2026.
The central nervous system consists of brain, spinal cord, and retina. The treatment of nervous system-related diseases includes infectious diseases, neurodegenerative diseases, autoimmune & inflammatory diseases, genetic disorders, cancers, trauma, and psychiatric disorders. The drugs such as analgesics, nervous system drugs, anesthetics, antiparkinson drugs, anti-epileptics, etc. are used for the disease treatment.
Browse the full “Central Nervous System Disorder Therapeutics Market By Disease Type (Infectious Diseases, Neurodegenerative Diseases, Autoimmune & Inflammatory Diseases, Genetic Disorders, Cancers, Trauma and Psychiatric Disorders), By Drug Type (Analgesics, Nervous System Drugs, Anesthetics, Anti-Parkinson Drugs, Anti-Epileptics, and Others) and By Distribution Channel (Hospitals, Clinics, Homecare and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" https://www.fnfresearch.com/central-nervous-system-disorder-therapeutics-market-by-disease-899
The prevalence of the neurological disorder has been increasing with the rising engagement of the population with digital and social media. This rise in CNS disorders has been increasing in both children and adults. With the rising concern, awareness about psychiatric disorders has increased. This has led to an increase in demand for therapeutic treatment of disorders.
The advancement in medical fields to develop a more effective drug delivery system is expected to increase the number of treatment-seeking individuals. Additionally, the rise in geriatric population in developed countries has further increased the rise in neurological disorders. According to the census, the older people population in the United States is expected to grow by an average of 2.3 million people per year until 2030.
However, the neurological services and resources are extremely limited, particularly in the low income and developing countries. Additionally, the policy-makers and health-care providers are expected to be underprepared for the anticipated rise in the prevalence of neurological and aging of people worldwide.
The psychiatric disorder and neurodegenerative disease are expected major disease responsible for the growth of the central nervous system disorder therapeutics market expansion. The number of young individuals experiencing mental health disorders of a certain type has grown sharply in the previous decade. Additionally, the rise in Alzheimer's disease especially, in Western countries is expected to propel the market for neurodegenerative disorder treatment.
North America is expected to hold largest share in the global central nervous system disorder therapeutics market. The key factors responsible for the market growth in North America are expected to be the rising number of psychiatric disorders, especially in the United States, growing geriatric population and presence of major pharmaceuticals company in the region. The European region is expected to hold second largest share followed by the Asia Pacific region. The United Kingdom, France and Germany are expected to be major contributor for the growth of market in the European region. The Asia Pacific region is anticipated to exhibit fastest growth rate among the regions. The Latin American and MEA region are expected to grow at significant rate owing to high prevalence of the epilepsy in Latin America and African countries like Nigeria, Liberia, and the United Republic of Tanzania. Parasitic infections, especially the neurocysticercosis, are key factors for rise in epilepsy in these countries.
Report Scope
Report Attribute |
Details |
Market Size in 2019 |
USD 81.9 Billion |
Projected Market Size in 2026 |
USD 104.2 Billion |
CAGR Growth Rate |
3.5% CAGR |
Base Year |
2019 |
Forecast Years |
2020-2026 |
Key Market Players |
Eli Lilly and Company, Inc., Johnson & Johnson Services, Inc., Biogen, Inc, AstraZeneca, Pfizer, Inc., Merck Shire Plc., & Co., Inc., Allergan Plc. Teva Pharmaceutical Industries Ltd.and Novartis AG. |
Key Segment |
By Product, By Quality, By Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
Major players operating in the central nervous system disorder therapeutics market mentioned in the report include Eli Lilly and Company, Inc., Johnson & Johnson Services, Inc., Biogen, Inc, AstraZeneca, Pfizer, Inc., Merck Shire Plc., & Co., Inc., Allergan Plc. Teva Pharmaceutical Industries Ltd.and Novartis AG.
This report segments the central nervous system disorder therapeutics market as follows:
Global Central Nervous System Disorder Therapeutics Market: By Product Segmentation Analysis
- Infectious Diseases
- Neurodegenerative Diseases
- Autoimmune & Inflammatory Diseases
- Genetic Disorders
- Cancers
- Trauma
- Psychiatric Disorders
Global Central Nervous System Disorder Therapeutics Market: By Quality Segmentation Analysis
- Analgesics
- Nervous System Drugs
- Anesthetics
- Anti-Parkinson Drugs
- Anti-Epileptics
- Others
Global Central Nervous System Disorder Therapeutics Market: Regional Segmentation Analysis
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A - 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com
